$200 Million

Tricida

Convertible Debt

Co-Manager, May 2020

Tricida

Tricida is a pharmaceutical company focused on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer designed to treat metabolic acidosis. Metabolic acidosis is a serious condition common caused by CKD that can result in accelerated progression of kidney disease.

More Like This

Jan 2021
$69 Million

Convertible Notes Restructuring

Exclusive Financial Advisor

View Details >
Nov 2020
$197 Million
Tilray Logo

Convertible Notes Exchange

Exclusive Financial Advisor

View Details >
Nov 2020
$1.15 Billion

Convertible Debt

Co-Manager

View Details >